Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of “Hold” by Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has been given an average rating of “Hold” by the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.50.

A number of equities research analysts have commented on the company. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Finally, HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research note on Friday.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of ANIX. Segall Bryant & Hamill LLC purchased a new position in Anixa Biosciences during the first quarter valued at $45,000. Renaissance Technologies LLC boosted its holdings in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after purchasing an additional 7,300 shares during the last quarter. Kestra Advisory Services LLC grew its position in shares of Anixa Biosciences by 96.2% during the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after purchasing an additional 25,000 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Anixa Biosciences in the fourth quarter worth about $161,000. Finally, Millennium Management LLC bought a new stake in shares of Anixa Biosciences in the fourth quarter worth about $38,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Trading Down 2.0%

NASDAQ ANIX traded down $0.05 on Friday, reaching $2.43. 34,881 shares of the stock were exchanged, compared to its average volume of 138,590. Anixa Biosciences has a one year low of $2.32 and a one year high of $5.46. The firm has a market capitalization of $81.48 million, a PE ratio of -7.84 and a beta of 0.59. The company’s 50-day simple moving average is $2.78 and its two-hundred day simple moving average is $3.10.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. Sell-side analysts forecast that Anixa Biosciences will post -0.38 earnings per share for the current fiscal year.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.